AI Article Synopsis
Article Abstract
Synchronous gastric cancer with another neoplasm is a rare condition, with colorectal cancer being the most frequently associated neoplasm. This article presents a case of a 76-year-old male diagnosed with synchronous gastric and rectal cancer with complete remission of gastric and rectal neoplasms after adjuvant therapy. The patient exhibited symptoms prompting upper and lower endoscopies, revealing gastric and rectal adenocarcinomas, respectively. Staging was performed, and due to the locally advanced nature of both malignancies, the patient underwent total neoadjuvant therapy (TNT) for rectal cancer. The treatment consisted of external radiotherapy and neoadjuvant chemotherapy with oxaliplatin, leucovorin, folinic acid, and fluorouracil (FOLFOX). Remarkably, after seven cycles, a complete clinical response of the rectal neoplasm was achieved. Subsequent surgical resection included simultaneous subtotal gastrectomy and rectal anterior resection, resulting in a complete pathological response for both tumors. To the best of our knowledge, it is among the first cases to report a full pathological response in gastric cancer following TNT intended for rectal cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11188006 | PMC |
| http://dx.doi.org/10.7759/cureus.60787 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Metachronous Schnitzler's Metastasis of Gastric Adenocarcinoma 13 Years After Curative Resection: A Case Report.
Korean J Gastroenterol
December 2024
Division of Gastroenterology, Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea.
A 54-year-old man presented with constipation with a six-month duration and a 5 kg weight loss over 10 months. He had undergone a subtotal gastrectomy and chemotherapy for advanced gastric cancer 13 years earlier. A colonoscopy revealed a firm, circular, in-growing mass in the rectum.
View Article and Find Full Text PDFContinuous prediction for tumor mutation burden based on transcriptional data in gastrointestinal cancers.
BMC Med Inform Decis Mak
December 2024
Department of Gastroenterology, First Affiliated Hospital of China Medical University, Shenyang, China.
Background: Tumor mutation burden (TMB) has been considered a biomarker for utilization of immune checkpoint inhibitors(ICIs), but whole exome sequencing(WES) and cancer gene panel(CGP) based on next generation sequencing for TMB detection are costly. Here, we use transcriptome data of TCGA to construct a model for TMB prediction in gastrointestinal tumors.
Methods: Transcriptome data, somatic mutation data and clinical data of four gastrointestinal tumors from TCGA, including esophageal cancer (ESCA), stomach adenocarcinoma (STAD), colon adenocarcinoma (COAD) and rectal adenocarcinoma (READ).
Epstein-Barr Virus Infection Presenting With Acute Gastrointestinal Involvement. Report of Two Cases of Epstein-Barr Virus Colitis in Kidney-Transplant Recipients and Scoping Review of the Literature.
J Med Virol
December 2024
IdiPAZ Hospital La Paz Institute for Health Research, La Paz University Hospital, Madrid, Spain.
Epstein-Barr virus (EBV) is a herpesvirus capable of establishing lifelong latent infections, leading to a wide spectrum of diseases. It can affect multiple organs, including the gastrointestinal tract, typically through lymphoproliferative syndromes or gastric cancer, while acute gastrointestinal disease is rare and poorly understood. Two cases of EBV-induced acute colitis in kidney transplant recipients were described.
View Article and Find Full Text PDFBody size and occupational physical activity during the life course and gastrointestinal cancers.
Am J Epidemiol
November 2024
Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, JapanNational Institutes of Health, Bethesda, MDJapan, USA.
Evidence on the associations of body size and occupational physical activity (PA) during the life course with gastrointestinal cancers is inconclusive. We analyzed data from the Golestan Cohort Study, a population-based prospective cohort study from Iran, with 50,045 individuals aged 40-75 years enrolled during 2004-2008 and followed through April 2023. Body size during adolescence, early adulthood, and at cohort baseline was assessed using validated pictograms.
View Article and Find Full Text PDFA real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for ramucirumab.
Expert Opin Drug Saf
December 2024
Department of Pharmacy, Pingtan Comprehensive Experimental Area Hospital, Fuzhou, PR China.
Background: Ramucirumab (IMC-1121B) is a fully human immunoglobulin G1 monoclonal antibody, approved by the US Food and Drug Administration (FDA) for treating various cancers, including gastric, colorectal, liver, and non-small cell lung cancer. This study aimed to investigate the adverse events (AEs) associated with ramucirumab by utilizing data mining techniques on the FDA Adverse Event Reporting System (FAERS).
Methods: We collected ramucirumab-related data from the FAERS database, spanning from January 2014 to June 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!